SP 2078

SP 2078 is a novel glycopeptide antibiotic that has greater potency, larger spectrum of activity, and longer post-antibiotic effect than has vancomycin. Although vancomycin remains the standard of care for gram positive infections caused by organisms resistant to β-lactam antibiotics, resistant organisms have emerged such as heterogenous vancomycin intermediate resistant Staphylococcus aureus (hVISA), vancomycin resistant S. aureus (VRSA), and VanA, VanB, and VanC resistant enterococci. SP 2078 has increased potency against vancomycin susceptible strains and restored activity against hVISA, VRSA, and VanB and VanC enterococci. SP 2078 is currently in preclinical development.